TAK-491 is an angiotensin receptor blocker (ARB) discovered by Takeda that lowers blood pressure. Takeda said that TAK-491 is expected to show stronger anti-hypertensive action, and also to have superior profile in improving the insulin resistance and decreasing proteinuria, as compared to existing ARBs on the market.
“We are pleased with the progress of TAK-491’s development stage into Phase III as this compound is expected to succeed our current mainstay product, candesartan, [sold under the brand Blopress] an ARB,” said Masaomi Miyamoto, general manager of Takeda’s pharmaceutical development division.
Dr Miyamoto went on to say that Takeda believes that TAK-475 will enhance the company’s most important therapeutic areas of metabolic diseases, including hypertension, diabetes and hypercholesterolemia among others.